Open ICICI
3-in-1 Account
Manage your Savings, Demat and Trading Account conveniently at one place
Manage your Savings, Demat and Trading Account conveniently at one place
News: Syngene announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent BioSolutions. The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. The overall investment in the US facility is estimated around US$50 million, including the cost of acquisition (US$36.5 million) and expenses to make the facility operational. The capacity will be will be available for client projects from second half of 2025.
View: This acquisition would be the maiden entry for Syngene in the US and this also holds importance in the backdrop of clients' requirement of having manufacturing facility in the US.
Impact: Positive